What Do You Know About Oxervate?

< Back to Homepage

Patient Selection For Oxervate

Wondering who might be a good candidate for treatment with the biologic Oxervate (cenegermin-bkbj)? W. Barry Lee, MD, FACS, and Clifford Salinger, MD, talk about the different classifications of neurotrophic keratitis and how they choose or identify patients who they believe will benefit from the drug.

More Videos


Supplement Cover

Breakthrough Therapy for Neurotrophic Keratitis

Marjan Farid, MD; Christopher J. Rapuano, MD; Kenneth A. Beckman, MD; Francis S. Mah, MD; and Marguerite B. McDonald, MD, share their experiences diagnosing and treating neurotrophic keratitis (NK) with Oxervate (cenegermin-bkbj). The physicians discuss common etiologies that lead to NK, what leads them to suspect the disease, and how Oxervate fits within current treatment options.

Read Supplement »
Beckman Headshot

Kenneth A. Beckman, MD

Farid Headshot

Marjan Farid, MD

Mah Headshot

Francis S. Mah, MD

McDonald Headshot

Marguerite B. McDonald, MD

Rapuano Headshot

Christopher J. Rapuano, MD